CN108434138A - 用于治疗与炎症相关的疾病的去乙基羟氯喹 - Google Patents

用于治疗与炎症相关的疾病的去乙基羟氯喹 Download PDF

Info

Publication number
CN108434138A
CN108434138A CN201810522358.9A CN201810522358A CN108434138A CN 108434138 A CN108434138 A CN 108434138A CN 201810522358 A CN201810522358 A CN 201810522358A CN 108434138 A CN108434138 A CN 108434138A
Authority
CN
China
Prior art keywords
disease
dhcq
inflammatory
inflammation
hcq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810522358.9A
Other languages
English (en)
Chinese (zh)
Inventor
威廉姆·H.·鲁滨逊
杰里米·索科洛夫
王倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Veterans Affairs
Leland Stanford Junior University
Original Assignee
United States Department of Veterans Affairs
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Veterans Affairs, Leland Stanford Junior University filed Critical United States Department of Veterans Affairs
Publication of CN108434138A publication Critical patent/CN108434138A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
CN201810522358.9A 2013-03-15 2014-03-14 用于治疗与炎症相关的疾病的去乙基羟氯喹 Pending CN108434138A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791320P 2013-03-15 2013-03-15
US61/791,320 2013-03-15
CN201480028469.4A CN105228453B (zh) 2013-03-15 2014-03-14 用于治疗与炎症相关的疾病的去乙基羟氯喹

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480028469.4A Division CN105228453B (zh) 2013-03-15 2014-03-14 用于治疗与炎症相关的疾病的去乙基羟氯喹

Publications (1)

Publication Number Publication Date
CN108434138A true CN108434138A (zh) 2018-08-24

Family

ID=51529979

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810522358.9A Pending CN108434138A (zh) 2013-03-15 2014-03-14 用于治疗与炎症相关的疾病的去乙基羟氯喹
CN201480028469.4A Expired - Fee Related CN105228453B (zh) 2013-03-15 2014-03-14 用于治疗与炎症相关的疾病的去乙基羟氯喹

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480028469.4A Expired - Fee Related CN105228453B (zh) 2013-03-15 2014-03-14 用于治疗与炎症相关的疾病的去乙基羟氯喹

Country Status (5)

Country Link
US (3) US9616057B2 (enExample)
EP (1) EP2967062A4 (enExample)
JP (1) JP6434487B2 (enExample)
CN (2) CN108434138A (enExample)
WO (1) WO2014144944A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096424A (zh) * 2020-09-14 2023-05-09 菲利普莫里斯生产公司 包含氯喹的药物组合物及其用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6434487B2 (ja) * 2013-03-15 2018-12-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 炎症を伴う疾患の治療のためのデスエチルヒドロキシクロロキン
US11501863B2 (en) 2015-04-09 2022-11-15 Diane R. MOULD Systems and methods for patient-specific dosing
WO2017189686A1 (en) * 2016-04-27 2017-11-02 The Board Of Regents Of The University Of Texas System Nurr1 activation in the treatment of metabolic disorders and as an exercise mimetic
CN108095767B (zh) * 2018-01-19 2020-10-02 无锡海斯凯尔医学技术有限公司 组织炎症活动度检测装置
US20200321096A1 (en) * 2019-03-08 2020-10-08 Diane R. MOULD Systems and methods for drug-agnostic patient-specific dosing regimens
GB2594918A (en) * 2020-03-30 2021-11-17 Blackhawk Partners Ltd A pharmaceutical composition comprising hydroxychloroquine, chloroquine, or metabolite thereof
EP3892275A1 (en) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hcq or its metabolites for the treatment of lung infections
WO2022113887A1 (ja) * 2020-11-27 2022-06-02 京都府公立大学法人 炎症性網膜疾患の判定方法、炎症性網膜疾患治療剤、及び炎症性網膜疾患治療剤のスクリーニング方法
JP2021051776A (ja) * 2020-12-15 2021-04-01 株式会社トプコン 医療情報処理システム及び医療情報処理方法
WO2022256426A1 (en) * 2021-06-04 2022-12-08 Genovate Biotechnology Co. Ltd. Treatment of antiphospholipid syndrome using s-hydroxychloroquine
CN114689770A (zh) * 2022-03-02 2022-07-01 上海长征医院 直接检测尿液中羟氯喹及其三种代谢产物的方法及检测试剂盒
CN115068478B (zh) * 2022-07-22 2024-01-09 上海医药工业有限公司 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA784722A (en) * 1968-05-07 W. Dennis Emery Desethylhydroxychloroquine as an anti-inflammatory agent
US20070003636A1 (en) * 2003-01-22 2007-01-04 Francois Mach Statins (HMG-COA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US20080044390A1 (en) * 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
WO2010127313A1 (en) * 2009-05-01 2010-11-04 Edenspace Systems Corporation Hmg-coa secondary metabolites and uses thereof
US20120202849A1 (en) * 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US341592A (en) * 1886-05-11 Eeubex a
US3019169A (en) * 1958-06-23 1962-01-30 Sterling Drug Inc Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process
US3415932A (en) 1965-05-18 1968-12-10 Sterling Drug Inc 7 - chloro - 4 - [4-(2-hydroxyethylamino)-1-methylbutylamino]quinoline; anti-inflammatory compositions and method using same
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
US7410975B2 (en) * 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US8440695B2 (en) 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
FR2898057B1 (fr) * 2006-03-06 2008-07-04 Centre Nat Rech Scient Utilisation de composes derives de l'adenine pour le traitement de lupus
EP3087988A3 (en) * 2008-10-06 2017-03-01 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
KR101813482B1 (ko) * 2010-11-24 2017-12-29 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 루푸스의 치료 또는 예방을 위한 조성물 및 방법
WO2014031769A2 (en) 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
JP6434487B2 (ja) * 2013-03-15 2018-12-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 炎症を伴う疾患の治療のためのデスエチルヒドロキシクロロキン

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA784722A (en) * 1968-05-07 W. Dennis Emery Desethylhydroxychloroquine as an anti-inflammatory agent
US20070003636A1 (en) * 2003-01-22 2007-01-04 Francois Mach Statins (HMG-COA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US20080044390A1 (en) * 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
WO2010127313A1 (en) * 2009-05-01 2010-11-04 Edenspace Systems Corporation Hmg-coa secondary metabolites and uses thereof
US20120202849A1 (en) * 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096424A (zh) * 2020-09-14 2023-05-09 菲利普莫里斯生产公司 包含氯喹的药物组合物及其用途

Also Published As

Publication number Publication date
CN105228453A (zh) 2016-01-06
US20170172998A1 (en) 2017-06-22
WO2014144944A1 (en) 2014-09-18
EP2967062A1 (en) 2016-01-20
US9616057B2 (en) 2017-04-11
JP2016518338A (ja) 2016-06-23
JP6434487B2 (ja) 2018-12-05
US9931335B2 (en) 2018-04-03
US20140275164A1 (en) 2014-09-18
US20180311231A1 (en) 2018-11-01
EP2967062A4 (en) 2016-10-19
CN105228453B (zh) 2018-05-22

Similar Documents

Publication Publication Date Title
CN105228453B (zh) 用于治疗与炎症相关的疾病的去乙基羟氯喹
US20140066469A1 (en) Treatment of diseases associated with inflammation
Beekman et al. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients
HK1252658A1 (zh) 治疗炎症或神经性疼痛的方法
JP2010500283A (ja) チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
JP2022533981A (ja) ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
TW202110451A (zh) 使用布魯頓酪胺酸激酶抑制劑治療休格倫氏症候群之方法
Fietta et al. Clodronate induced uveitis
KR20230106644A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
JP2019521160A (ja) Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド
KR102893744B1 (ko) 피리메타민을 유효성분으로 포함하는 류마티스 관절염의 치료 또는 예방용 약학 조성물
Tracey Diagnosis and management of rheumatoid arthritis
JP2005505605A (ja) 前痴呆状態におけるロスバスタチン
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
US12600715B2 (en) Soluble guanylate cyclate activators for treating systemic sclerosis
Hemadri et al. Chapter-3 Rheumatoid Arthritis: A Comprehensive Review of Etiology, Diagnosis, and Therapeutic Strategies
JP2015101585A (ja) 中枢神経系自己免疫疾患治療用のアンジオテンシン変換酵素阻害剤
CN120771133A (zh) 原发性胆汁性胆管炎的长期治疗
WO2023059714A1 (en) Methods of treating estrogen receptor-mediated disorders
Hamada et al. Immune System Diseases
Walhelm et al. POS1145 FACTORS ASSOCIATED WITH SURVIVAL AND DISCONTINUATION OF ANTIMALARIAL AGENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A SWEDISH LONGITUDINAL REGISTRY
CN120500340A (zh) 用于治疗原发性膜性肾病的方法
HK40061449A (en) Methods of treating inflammation or neuropathic pain
EA051816B1 (ru) Способы лечения с применением lou064

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180824